Physician profile
Noor Daoud
NPI 1205244019
$5,149.56
in general payments reported to CMS, 2019-2025
34 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,971 · 2022: $1,332 · 2023: $1,293 · 2024: $430 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,846.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $516.27 | 2021-2024 | Bexsero, Arexvy, Shingrix |
| Lilly USA, LLC | $489.93 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $437.36 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Amarin Pharma, INC. | $430.28 | 2021-2023 | |
| Abbvie INC. | $358.40 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $262.41 | 2021-2024 | Farxiga, Fasenra, Airsupra |
| Pfizer INC. | $252.61 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $244.93 | 2021-2025 | |
| Abbott Laboratories | $215.20 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $201.18 | 2021-2024 | Otezla, Repatha, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $189.83 | 2021-2022 | |
| Merz North America, INC. | $162.14 | 2023 | Xeomin |
| Idorsia Pharmaceuticals US INC | $150.97 | 2022-2024 | Quviviq |
| Lundbeck LLC | $140.27 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.30 | 2021-2023 | Xifaxan, Relistor |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.95 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $101.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $94.43 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $81.97 | 2022 | |
| Sanofi-Aventis U.S. LLC | $79.69 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $77.66 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $63.13 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $61.99 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $49.43 | 2021 | |
| Dexcom, INC. | $49.32 | 2021-2023 | Dexcom G6 Transmitter |
| Eisai INC. | $35.99 | 2021 | |
| Upsher-Smith Laboratories LLC | $35.25 | 2021 | |
| Dynavax Technologies Corporation | $20.44 | 2023 | Heplisav-B |
| Astellas Pharma US INC | $18.57 | 2024 | Veozah |
| Medtronic, INC. | $18.46 | 2022 | |
| Daiichi Sankyo INC. | $17.18 | 2021 | |
| Currax Pharmaceuticals LLC | $14.31 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.02 | 2021 | |
| Hikma Pharmaceuticals USA | $14.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noor Daoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.